📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

🧪

Mock / simulation document

This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.

📄

About this document — a plain-language guide

What it is. The FDA risk-management assessment and REMS (Risk Evaluation and Mitigation Strategy) analysis — whether extra safety controls beyond labeling are needed.

Why it exists. For some drugs the FDA requires a REMS: measures such as a Medication Guide, communication plans, or controlled distribution to ensure benefits outweigh risks. This document assesses whether GLPI-103's risk profile requires one.

How it is produced here. This is a region-specific administrative document, assembled to the local filing and labeling conventions. Its operational and label content is written to stay consistent with the (simulated) clinical data.

Format & governing standard. FDAAA §505-1 (REMS) · 21 CFR 208 (Medication Guide) · 21 CFR 201.57 (PLR)

FDA Risk Management & REMS Assessment — GLPI-103

Field	Value
Document ID	RMP-US
Version	2.0 (full)
Compound	GLPI-103 (GLP-1/APJ dual agonist)
Region	FDA (US)
Standard	FDAAA §505-1 (REMS) · 21 CFR 208 (Medication Guide) · 21 CFR 201.57 (PLR)
Confidentiality	Confidential

Uses the master safety specification from the EU-RMP (RMP-EU Part II). US risk management emphasizes labeling and the Medication Guide, consistent with the GLP-1 receptor agonist class.

Change History

Version	Date	Author	Summary
1.0	2026-06-29	Pharmacovigilance / Regulatory	Initial assessment
2.0	2026-06-29	Pharmacovigilance / Regulatory	Full — REMS framework analysis, labeling detail, PV plan

1. Safety Concerns (per RMP-EU Part II)

Important identified risks: gastrointestinal adverse events; hypoglycaemia (with insulin secretagogues). Important potential risks: acute pancreatitis; thyroid C-cell tumours (MTC/MEN2); cardiovascular/heart-rate effects (APJ-mediated); immunogenicity. Missing information: pregnancy/lactation; paediatric use; severe renal/hepatic impairment; long-term and cardiovascular-outcomes safety.

2. REMS Necessity Assessment (FDAAA §505-1)

The determination of whether a REMS is required weighs: the seriousness of known/potential adverse events; the expected benefit; the duration of treatment; the seriousness of the disease; and the size of the treated population. Applying this framework:

The identified and potential risks are consistent with the approved GLP-1 receptor agonist class and are well characterized.
These risks have historically been manageable by routine, labeling-based risk management for approved GLP-1 products (which generally do not carry a REMS).
The gastrointestinal and hypoglycaemia risks are manageable through titration and prescriber awareness; the potential risks (pancreatitis, thyroid C-cell) are addressed through contraindications, warnings, and the Medication Guide.

Conclusion: the benefits of routine risk management outweigh the incremental value of REMS elements; a REMS is not proposed. This determination will be re-evaluated if post-marketing data indicate a new or disproportionate risk not adequately mitigated by labeling.

3. Routine Risk Management — US Prescribing Information

Boxed Warning — Thyroid C-cell tumours: consistent with the GLP-1 class; contraindication in patients with a personal or family history of MTC or MEN 2.
Contraindications: personal/family history of MTC or MEN 2; prior serious hypersensitivity to GLPI-103.
Warnings and Precautions: acute pancreatitis (discontinue if suspected); gastrointestinal adverse reactions (titrate; risk of dehydration/renal effects with severe events); hypoglycaemia with concomitant insulin/secretagogues (consider dose reduction of the secretagogue); cardiovascular/heart-rate monitoring (mechanism-related).
Adverse Reactions: the most common were gastrointestinal; nausea 32.3% (IV) vs 21.4% (comparator), not significantly different (CSR-301 §12).
Use in Specific Populations: pregnancy/lactation (limited data); renal/hepatic impairment (not studied in severe impairment); paediatric (not established).

4. Medication Guide (21 CFR 208)

A patient Medication Guide is dispensed, addressing: recognition of symptoms of thyroid tumours and acute pancreatitis; management of gastrointestinal effects through titration; and hypoglycaemia precautions when used with other glucose-lowering medicines.

5. Pharmacovigilance

Routine pharmacovigilance (FAERS signal detection; 15-day expedited and periodic safety reporting); targeted follow-up for pancreatitis and MTC; a pregnancy exposure registry; and a post-marketing long-term/cardiovascular safety study (aligned with the EU PASS, RMP-EU Part III).

6. Conclusion

GLPI-103's risks are adequately managed by routine, labeling-based risk minimization (including a class boxed warning and a Medication Guide) together with routine and post-marketing pharmacovigilance; no REMS is warranted at approval.